Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
11.03.2022 - Currently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimer’s Disease (Phase 2a), and Covid-related Acute Respiratory Distress Syndrome (Phase 1) Lomecel-B for HLHS ...
Source: wallstreet-online.de